Sugi Predict

Sugi Predict / Targets / KDM5B

KDM5B

Lysine-specific demethylase 5B · Q9UGL1 · KDM5B on Sugi Atlas →

45,498 patent compounds predicted against KDM5B, 23,285 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL449879 SCHEMBL449879 0.63 8/20
SCHEMBL70700 SCHEMBL70700 0.70 7/20
SCHEMBL528023 SCHEMBL528023 0.68 7/20
SCHEMBL582010 SCHEMBL582010 0.56 7/20
SCHEMBL440809 SCHEMBL440809 0.54 7/20
SCHEMBL481039 SCHEMBL481039 0.52 7/20
SCHEMBL528803 SCHEMBL528803 0.49 7/20
SCHEMBL442839 SCHEMBL442839 0.48 7/20
SCHEMBL463720 SCHEMBL463720 0.44 7/20
SCHEMBL118817 SCHEMBL118817 0.61 6/20
SCHEMBL353289 SCHEMBL353289 0.61 6/20
SCHEMBL509374 SCHEMBL509374 0.50 6/20
SCHEMBL214254 SCHEMBL214254 0.36 6/20
SCHEMBL215558 SCHEMBL215558 0.33 6/20
SCHEMBL40395 SCHEMBL40395 0.61 5/20
SCHEMBL581690 SCHEMBL581690 0.55 5/20
SCHEMBL580683 SCHEMBL580683 0.48 5/20
SCHEMBL528024 SCHEMBL528024 0.47 5/20
SCHEMBL215624 SCHEMBL215624 0.34 5/20
SCHEMBL72377 SCHEMBL72377 1.00 4/20

Clinical trials — most relevant to KDM5B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors PHASE2RECRUITING
Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2 PHASE2ACTIVE_NOT_RECRUITING
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations PHASE2SUSPENDED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors PHASE1RECRUITING
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors PHASE1COMPLETED
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma PHASE1RECRUITING
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors PHASE1RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
The Danish TURNER Cryopreservation Study nanRECRUITING
Lysine-specific Demethylase 1 and Salt-sensitivity in Humans nanACTIVE_NOT_RECRUITING
The Crosstalk Between the Epigenome and Mitochondria in SCI nanNOT_YET_RECRUITING
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19 nanCOMPLETED
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer nanUNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
MIF Involvement in AML nanACTIVE_NOT_RECRUITING
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer nanUNKNOWN
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy nanRECRUITING
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia nanUNKNOWN
Mechanisms of Immune Deficiency nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Study on Recurrence Monitoring of Hepatocellular Carcinoma With 5-Hydroxymethylcytosine Test nanUNKNOWN
COPENHAGEN Minipuberty Study nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a KDM5B binder may also engage these)

ProteinNameSimilarity
Q80Y84 — 1.000 Q80Y84 →
Q5F3R2 — 1.000 Q5F3R2 →
KDM5D Lysine-specific demethylase 5D 1.000 landscape →
Q6IQX0 — 1.000 Q6IQX0 →
Q5XUN4 — 1.000 Q5XUN4 →
Q62240 — 1.000 Q62240 →
P41230 — 1.000 P41230 →
A1YVX4 — 1.000 A1YVX4 →
Q3UXZ9 — 1.000 Q3UXZ9 →
Q30DN6 — 1.000 Q30DN6 →
Q61T02 — 1.000 Q61T02 →
KDM5C Lysine-specific demethylase 5C 1.000 landscape →
Q38JA7 — 1.000 Q38JA7 →
KAT8 Histone acetyltransferase KAT8 0.999 landscape →
Q9VMJ7 — 0.998 Q9VMJ7 →
Q5XI06 — 0.998 Q5XI06 →
Q7Z401 — 0.997 Q7Z401 →
DHX29 ATP-dependent RNA helicase DHX29 0.996 landscape →
KDM5A Lysine-specific demethylase 5A 0.996 landscape →
P25799 — 0.995 P25799 →
Q9H1H9 — 0.995 Q9H1H9 →
Q8BX57 — 0.995 Q8BX57 →
A2CEA7 — 0.995 A2CEA7 →
Q9W3D3 — 0.995 Q9W3D3 →
Q5U379 — 0.995 Q5U379 →
Q8VCD7 — 0.995 Q8VCD7 →
Q9V333 — 0.994 Q9V333 →
Q23541 — 0.994 Q23541 →
A3KMI0 — 0.994 A3KMI0 →
Q03603 — 0.994 Q03603 →